# Insulet Corp: overview

PODD · Nasdaq · CIK 1145197 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/podd.md) · [Financials](/companies/podd/financials.md) · [Filings](/companies/podd/filings.md) · [Insiders](/companies/podd/insiders.md)

Latest reported revenue: [$801.7m](/filings/0001145197-26-000169.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0001145197-26-000169).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [544](/filings/0001145197-25-000069.md) | [598 d](/filings/0001145197-26-000028.md) | [569](/filings/0001145197-26-000102.md) | [649](/filings/0001145197-26-000169.md) | [706](/filings/0001145197-25-000069.md) | [784 d](/filings/0001145197-26-000028.md) | [762](/filings/0001145197-26-000102.md) | [802](/filings/0001145197-26-000169.md) |
| Gross margin | % | [69.3%](/filings/0001145197-25-000069.md) | [72.1% d](/filings/0001145197-26-000028.md) | [71.9%](/filings/0001145197-26-000102.md) | [69.7%](/filings/0001145197-26-000169.md) | [72.2%](/filings/0001145197-25-000069.md) | [72.5% d](/filings/0001145197-26-000028.md) | [69.5%](/filings/0001145197-26-000102.md) | [70.2%](/filings/0001145197-26-000169.md) |
| Operating margin | % | [16.2%](/filings/0001145197-25-000069.md) | [18.3% d](/filings/0001145197-26-000028.md) | [15.6%](/filings/0001145197-26-000102.md) | [18.7%](/filings/0001145197-26-000169.md) | [16.7%](/filings/0001145197-25-000069.md) | [18.7% d](/filings/0001145197-26-000028.md) | [16.0%](/filings/0001145197-26-000102.md) | [16.2%](/filings/0001145197-26-000169.md) |
| Net margin | % | [14.2%](/filings/0001145197-25-000069.md) | [16.9% d](/filings/0001145197-26-000028.md) | [6.2%](/filings/0001145197-26-000102.md) | [3.5%](/filings/0001145197-26-000169.md) | [12.4%](/filings/0001145197-25-000069.md) | [13.0% d](/filings/0001145197-26-000028.md) | [12.0%](/filings/0001145197-26-000102.md) | [11.8%](/filings/0001145197-26-000169.md) |
| Diluted EPS | $ per share | [1.08](/filings/0001145197-25-000069.md) | not reported | [0.50](/filings/0001145197-26-000102.md) | [0.32](/filings/0001145197-26-000169.md) | [1.24](/filings/0001145197-25-000069.md) | not reported | [1.30](/filings/0001145197-26-000102.md) | [1.37](/filings/0001145197-26-000169.md) |
| Free cash flow | $m | [81.6 d](/filings/0001145197-25-000069.md) | [93.9 d](/filings/0001145197-26-000028.md) | [51.5](/filings/0001145197-26-000102.md) | [178 d](/filings/0001145197-26-000169.md) | [100 d](/filings/0001145197-25-000069.md) | [48.2 d](/filings/0001145197-26-000028.md) | [89.5](/filings/0001145197-26-000102.md) | [55.9 d](/filings/0001145197-26-000169.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,041](/filings/0001145197-23-000020.md) | [1,055](/filings/0001145197-23-000020.md) | [1,697](/filings/0001145197-26-000028.md) | [2,072](/filings/0001145197-26-000028.md) | [2,708](/filings/0001145197-26-000028.md) |
| Gross margin | % | [72.3%](/filings/0001145197-24-000011.md) | [76.3%](/filings/0001145197-25-000007.md) | [68.3%](/filings/0001145197-26-000028.md) | [69.8%](/filings/0001145197-26-000028.md) | [71.6%](/filings/0001145197-26-000028.md) |
| Operating margin | % | [12.1%](/filings/0001145197-24-000011.md) | [3.6%](/filings/0001145197-25-000007.md) | [13.0%](/filings/0001145197-26-000028.md) | [14.9%](/filings/0001145197-26-000028.md) | [17.5%](/filings/0001145197-26-000028.md) |
| Net margin | % | [1.6%](/filings/0001145197-24-000011.md) | [0.4%](/filings/0001145197-25-000007.md) | [12.2%](/filings/0001145197-26-000028.md) | [20.2%](/filings/0001145197-26-000028.md) | [9.1%](/filings/0001145197-26-000028.md) |
| Diluted EPS | $ per share | [0.24](/filings/0001145197-24-000011.md) | [0.07](/filings/0001145197-25-000007.md) | [2.94](/filings/0001145197-26-000028.md) | [5.78](/filings/0001145197-26-000028.md) | [3.48](/filings/0001145197-26-000028.md) |
| Free cash flow | $m | [(180)](/filings/0001145197-24-000011.md) | [(3.9)](/filings/0001145197-25-000007.md) | [70.1](/filings/0001145197-26-000028.md) | [305](/filings/0001145197-26-000028.md) | [378](/filings/0001145197-26-000028.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/podd/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.02bn | 6,690,192 |  | Added +314,249 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $689.0m | 4,525,333 |  | Reduced −53,941 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $486.8m | 3,197,555 |  | Added +155,101 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $468.3m | 3,075,932 |  | Reduced −374,055 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $373.8m | 2,455,135 |  | Added +856,411 |
| [BAILLIE GIFFORD & CO](/funds/1088875.md) | 2026-06-30 | $310.9m | 2,042,313 |  | Added +12,821 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $304.0m | 2,003,861 |  | Reduced −21,837 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $289.8m | 1,903,734 |  | Added +1,141,385 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $258.0m | 1,694,651 |  | Added +598,114 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $225.2m | 1,479,050 |  | Added +333,119 |

## Recent filings

[All 1,542 filings](/companies/podd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-21 | 21:02 ET | [8-K](/filings/0001193125-26-396779.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-396779 |
| 2026-09-16 | 20:03 ET | [8-K](/filings/0001145197-26-000177.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001145197-26-000177 |
| 2026-09-10 | 20:02 ET | [8-K](/filings/0001145197-26-000175.md) | 5.02 Departure or appointment of officers or directors | 0001145197-26-000175 |
| 2026-08-05 | 20:06 ET | [10-Q](/filings/0001145197-26-000169.md) | Quarterly report, period 2026-06-30 | 0001145197-26-000169 |
| 2026-08-05 | 11:04 ET | [8-K](/filings/0001145197-26-000167.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001145197-26-000167 |
| 2026-06-25 | 11:06 ET | [8-K](/filings/0001145197-26-000148.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001145197-26-000148 |
| 2026-05-26 | 20:06 ET | [8-K](/filings/0001145197-26-000132.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001145197-26-000132 |
| 2026-05-21 | 20:03 ET | [8-K](/filings/0001145197-26-000121.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001145197-26-000121 |
| 2026-05-06 | 20:03 ET | [10-Q](/filings/0001145197-26-000102.md) | Quarterly report, period 2026-03-31 | 0001145197-26-000102 |
| 2026-05-06 | 11:05 ET | [8-K](/filings/0001145197-26-000100.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001145197-26-000100 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001145197-26-000028.md), filed Feb 18, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5d1c540f-3bc0-4e59-8111-e2cbcdb12925)

## About the filer

- CIK: 1145197
- Tickers: PODD
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.